Correction to: Breast Cancer Res
https://doi.org/10.1186/s13058-019-1196-y
After the publication [1] the authors report corrections for Table 3, for the headers of columns 5 and 7, which should read as follows: Column 5 Header: P-value for pCR, T vs Other Arms in HR+, and Column 7 Header: P-value for pCR, T vs Other Arms in HR–.
The correct version of the table can be found below:
Reference
Jacobs, et al. Breast Cancer Res. 2019;21:133. https://doi.org/10.1186/s13058-019-1196-y.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Jacobs, S.A., Robidoux, A., Abraham, J. et al. Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Res 22, 9 (2020). https://doi.org/10.1186/s13058-019-1240-y
Published:
DOI: https://doi.org/10.1186/s13058-019-1240-y